BRWA
CBAY

B. Riley Wealth Advisors’s Cymabay Therapeutics CBAY Stock Holding History

B. Riley Wealth Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,275
Closed -$16K – 911
2020
Q1 		$16K Sell
10,275
-5,550
-35% -$9.32K ﹤0.01% 779
2019
Q4 		$32K Sell
15,825
-8,100
-34% -$30.4K ﹤0.01% 822
2019
Q3 		$123K Buy
23,925
+1,000
+4% +$6.05K 0.01% 760
2019
Q2 		$165K Buy
+22,925
New +$260K 0.02% 731

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

B. Riley Wealth Advisors's CBAY Position: Q2 2020 in Review

B. Riley Wealth Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2020, closing a stake of 10,275 shares — an estimated $16K sold.

B. Riley Wealth Advisors first reported a position in CBAY in Q2 2019 and held it in 4 quarters. The position peaked at $165K in Q2 2019. 114 funds tracked by Wall St. Rank hold CBAY as of Q2 2020.

  • B. Riley Wealth Advisors reported no remaining Cymabay Therapeutics position as of Q2 2020 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 10,275 Cymabay Therapeutics shares in Q2 2020, an estimated $16K.
  • B. Riley Wealth Advisors first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 4 quarters.
  • B. Riley Wealth Advisors's Cymabay Therapeutics position peaked at $165K in Q2 2019.
  • 114 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2020.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2020, filed 31 Jul 2020.